ID   QPCT_HUMAN              Reviewed;         361 AA.
AC   Q16769; Q16770; Q3KRG6; Q53TR4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   10-MAY-2017, entry version 145.
DE   RecName: Full=Glutaminyl-peptide cyclotransferase;
DE            EC=2.3.2.5;
DE   AltName: Full=Glutaminyl cyclase;
DE            Short=QC;
DE            Short=sQC;
DE   AltName: Full=Glutaminyl-tRNA cyclotransferase;
DE   AltName: Full=Glutamyl cyclase;
DE            Short=EC;
DE   Flags: Precursor;
GN   Name=QPCT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Pituitary;
RX   PubMed=7999256; DOI=10.1677/jme.0.0130077;
RA   Song I., Chuang C.Z., Bateman R.C. Jr.;
RT   "Molecular cloning, sequence analysis and expression of human
RT   pituitary glutaminyl cyclase.";
RL   J. Mol. Endocrinol. 13:77-86(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-360.
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION AS GLUTAMYL CYCLASE.
RX   PubMed=15063747; DOI=10.1016/S0014-5793(04)00300-X;
RA   Schilling S., Hoffmann T., Manhart S., Hoffmann M., Demuth H.U.;
RT   "Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid
RT   conditions.";
RL   FEBS Lett. 563:191-196(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18486145; DOI=10.1016/j.jmb.2008.03.078;
RA   Cynis H., Rahfeld J.U., Stephan A., Kehlen A., Koch B., Wermann M.,
RA   Demuth H.U., Schilling S.;
RT   "Isolation of an isoenzyme of human glutaminyl cyclase: retention in
RT   the Golgi complex suggests involvement in the protein maturation
RT   machinery.";
RL   J. Mol. Biol. 379:966-980(2008).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 33-361, CATALYTIC ACTIVITY,
RP   MUTAGENESIS OF LYS-144; PHE-146; GLU-201; TRP-207; ASP-248; GLN-304;
RP   ASP-305; PHE-325 AND TRP-329, AND CHARACTERIZATION OF VARIANT TRP-54.
RX   PubMed=16135565; DOI=10.1073/pnas.0504184102;
RA   Huang K.-F., Liu Y.-L., Cheng W.-J., Ko T.-P., Wang A.H.-J.;
RT   "Crystal structures of human glutaminyl cyclase, an enzyme responsible
RT   for protein N-terminal pyroglutamate formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13117-13122(2005).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 33-361 OF MUTANTS ALA-160;
RP   GLY-160; ASP-201; LEU-201; GLN-201; ALA-248; GLN-248; ALA-305; GLU-305
RP   AND LEU-319 IN COMPLEX WITH ZINC IONS, CATALYTIC ACTIVITY, COFACTOR,
RP   ACTIVE SITE, AND MUTAGENESIS OF SER-160; GLU-201; ASP-248; ASP-305 AND
RP   HIS-319.
RX   PubMed=18072935; DOI=10.1042/BJ20071073;
RA   Huang K.F., Wang Y.R., Chang E.C., Chou T.L., Wang A.H.;
RT   "A conserved hydrogen-bond network in the catalytic centre of animal
RT   glutaminyl cyclases is critical for catalysis.";
RL   Biochem. J. 411:181-190(2008).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 38-361, GLYCOSYLATION AT
RP   ASN-49, AND DISULFIDE BOND.
RX   PubMed=21671571; DOI=10.1021/bi200249h;
RA   Ruiz-Carrillo D., Koch B., Parthier C., Wermann M., Dambe T.,
RA   Buchholz M., Ludwig H.H., Heiser U., Rahfeld J.U., Stubbs M.T.,
RA   Schilling S., Demuth H.U.;
RT   "Structures of glycosylated mammalian glutaminyl cyclases reveal
RT   conformational variability near the active center.";
RL   Biochemistry 50:6280-6288(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 33-361 IN COMPLEX WITH ZINC
RP   IONS, CATALYTIC ACTIVITY, FUNCTION, AND COFACTOR.
RX   PubMed=21288892; DOI=10.1074/jbc.M110.208595;
RA   Huang K.F., Liaw S.S., Huang W.L., Chia C.Y., Lo Y.C., Chen Y.L.,
RA   Wang A.H.;
RT   "Structures of human Golgi-resident glutaminyl cyclase and its
RT   complexes with inhibitors reveal a large loop movement upon inhibitor
RT   binding.";
RL   J. Biol. Chem. 286:12439-12449(2011).
CC   -!- FUNCTION: Responsible for the biosynthesis of pyroglutamyl
CC       peptides. Has a bias against acidic and tryptophan residues
CC       adjacent to the N-terminal glutaminyl residue and a lack of
CC       importance of chain length after the second residue. Also
CC       catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes
CC       pyroglutamate formation of N-terminally truncated form of APP
CC       amyloid-beta peptides [Glu-3]-beta-amyloid. May be involved in the
CC       N-terminal pyroglutamate formation of several amyloid-related
CC       plaque-forming peptides. {ECO:0000269|PubMed:15063747,
CC       ECO:0000269|PubMed:18486145, ECO:0000269|PubMed:21288892}.
CC   -!- CATALYTIC ACTIVITY: L-glutaminyl-peptide = 5-oxoprolyl-peptide +
CC       NH(3). {ECO:0000269|PubMed:16135565, ECO:0000269|PubMed:18072935,
CC       ECO:0000269|PubMed:18486145, ECO:0000269|PubMed:21288892}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:18072935,
CC         ECO:0000269|PubMed:21288892};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:18072935,
CC       ECO:0000269|PubMed:21288892};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:18486145}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16769-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16769-2; Sequence=VSP_038487;
CC   -!- SIMILARITY: Belongs to the glutaminyl-peptide cyclotransferase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X71125; CAA50438.1; -; mRNA.
DR   EMBL; X67731; CAA47961.1; -; mRNA.
DR   EMBL; AK290605; BAF83294.1; -; mRNA.
DR   EMBL; AC007391; AAY14804.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00392.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00394.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00396.1; -; Genomic_DNA.
DR   EMBL; BC036721; AAH36721.1; -; mRNA.
DR   EMBL; BC047756; AAH47756.1; -; mRNA.
DR   CCDS; CCDS1790.1; -. [Q16769-1]
DR   PIR; I37421; I37421.
DR   RefSeq; NP_036545.1; NM_012413.3. [Q16769-1]
DR   UniGene; Hs.79033; -.
DR   PDB; 1MOI; Model; -; A=1-361.
DR   PDB; 2AFM; X-ray; 1.66 A; A/B=33-361.
DR   PDB; 2AFO; X-ray; 2.35 A; A/B=33-361.
DR   PDB; 2AFS; X-ray; 2.22 A; A/B=33-361.
DR   PDB; 2AFU; X-ray; 2.22 A; A/B=33-361.
DR   PDB; 2AFW; X-ray; 1.56 A; A/B=33-361.
DR   PDB; 2AFX; X-ray; 1.64 A; A/B=33-361.
DR   PDB; 2AFZ; X-ray; 1.68 A; A/B=33-361.
DR   PDB; 2ZED; X-ray; 1.70 A; A/B=33-361.
DR   PDB; 2ZEE; X-ray; 1.99 A; A/B=33-361.
DR   PDB; 2ZEF; X-ray; 1.67 A; A/B=33-361.
DR   PDB; 2ZEG; X-ray; 2.08 A; A/B=33-361.
DR   PDB; 2ZEH; X-ray; 1.80 A; A/B=33-361.
DR   PDB; 2ZEL; X-ray; 1.97 A; A/B=33-361.
DR   PDB; 2ZEM; X-ray; 2.18 A; A/B=33-361.
DR   PDB; 2ZEN; X-ray; 1.78 A; A/B=33-361.
DR   PDB; 2ZEO; X-ray; 1.66 A; A/B=33-361.
DR   PDB; 2ZEP; X-ray; 2.10 A; A/B=33-361.
DR   PDB; 3PBB; X-ray; 1.95 A; A/B=33-361.
DR   PDB; 3PBE; X-ray; 1.95 A; A/B=33-361.
DR   PDB; 3SI0; X-ray; 2.10 A; A=38-361.
DR   PDB; 4YU9; X-ray; 2.10 A; A/B/C=33-361.
DR   PDB; 4YWY; X-ray; 1.95 A; A/B/C=1-361.
DR   PDBsum; 1MOI; -.
DR   PDBsum; 2AFM; -.
DR   PDBsum; 2AFO; -.
DR   PDBsum; 2AFS; -.
DR   PDBsum; 2AFU; -.
DR   PDBsum; 2AFW; -.
DR   PDBsum; 2AFX; -.
DR   PDBsum; 2AFZ; -.
DR   PDBsum; 2ZED; -.
DR   PDBsum; 2ZEE; -.
DR   PDBsum; 2ZEF; -.
DR   PDBsum; 2ZEG; -.
DR   PDBsum; 2ZEH; -.
DR   PDBsum; 2ZEL; -.
DR   PDBsum; 2ZEM; -.
DR   PDBsum; 2ZEN; -.
DR   PDBsum; 2ZEO; -.
DR   PDBsum; 2ZEP; -.
DR   PDBsum; 3PBB; -.
DR   PDBsum; 3PBE; -.
DR   PDBsum; 3SI0; -.
DR   PDBsum; 4YU9; -.
DR   PDBsum; 4YWY; -.
DR   ProteinModelPortal; Q16769; -.
DR   SMR; Q16769; -.
DR   BioGrid; 117329; 19.
DR   IntAct; Q16769; 3.
DR   STRING; 9606.ENSP00000344829; -.
DR   BindingDB; Q16769; -.
DR   ChEMBL; CHEMBL4508; -.
DR   DrugBank; DB04581; 1-benzylimidazole.
DR   DrugBank; DB04636; Glutamine t-butyl ester.
DR   DrugBank; DB04622; N-ACETYLHISTAMINE.
DR   GuidetoPHARMACOLOGY; 2411; -.
DR   MEROPS; M28.974; -.
DR   iPTMnet; Q16769; -.
DR   PhosphoSitePlus; Q16769; -.
DR   BioMuta; QPCT; -.
DR   DMDM; 2498824; -.
DR   PaxDb; Q16769; -.
DR   PeptideAtlas; Q16769; -.
DR   PRIDE; Q16769; -.
DR   TopDownProteomics; Q16769-2; -. [Q16769-2]
DR   DNASU; 25797; -.
DR   Ensembl; ENST00000338415; ENSP00000344829; ENSG00000115828. [Q16769-1]
DR   GeneID; 25797; -.
DR   KEGG; hsa:25797; -.
DR   UCSC; uc002rqg.4; human. [Q16769-1]
DR   CTD; 25797; -.
DR   DisGeNET; 25797; -.
DR   GeneCards; QPCT; -.
DR   HGNC; HGNC:9753; QPCT.
DR   HPA; HPA008406; -.
DR   MIM; 607065; gene.
DR   neXtProt; NX_Q16769; -.
DR   OpenTargets; ENSG00000115828; -.
DR   PharmGKB; PA34095; -.
DR   eggNOG; KOG3946; Eukaryota.
DR   eggNOG; ENOG410YIYE; LUCA.
DR   GeneTree; ENSGT00390000003107; -.
DR   HOGENOM; HOG000189291; -.
DR   HOVERGEN; HBG009812; -.
DR   InParanoid; Q16769; -.
DR   KO; K00683; -.
DR   OMA; SVWHTFD; -.
DR   OrthoDB; EOG091G09N2; -.
DR   PhylomeDB; Q16769; -.
DR   TreeFam; TF315071; -.
DR   BRENDA; 2.3.2.5; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   ChiTaRS; QPCT; human.
DR   EvolutionaryTrace; Q16769; -.
DR   GeneWiki; QPCT; -.
DR   GenomeRNAi; 25797; -.
DR   PRO; PR:Q16769; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115828; -.
DR   CleanEx; HS_QPCT; -.
DR   ExpressionAtlas; Q16769; baseline and differential.
DR   Genevisible; Q16769; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0016603; F:glutaminyl-peptide cyclotransferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0017186; P:peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase; IDA:UniProtKB.
DR   InterPro; IPR007484; Peptidase_M28.
DR   Pfam; PF04389; Peptidase_M28; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Alternative splicing;
KW   Complete proteome; Disulfide bond; Glycoprotein; Metal-binding;
KW   Polymorphism; Reference proteome; Secreted; Signal; Transferase; Zinc.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   CHAIN        29    361       Glutaminyl-peptide cyclotransferase.
FT                                /FTId=PRO_0000022195.
FT   ACT_SITE    201    201       Proton acceptor.
FT                                {ECO:0000269|PubMed:18072935}.
FT   ACT_SITE    248    248       Proton acceptor.
FT                                {ECO:0000269|PubMed:18072935}.
FT   METAL       159    159       Zinc; catalytic.
FT   METAL       202    202       Zinc; catalytic.
FT   METAL       330    330       Zinc; catalytic.
FT   CARBOHYD     49     49       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:21671571}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    139    164       {ECO:0000269|PubMed:21671571}.
FT   VAR_SEQ      41     89       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_038487.
FT   VARIANT      54     54       R -> W (lowers activity by approximately
FT                                30%; dbSNP:rs2255991).
FT                                {ECO:0000269|PubMed:16135565}.
FT                                /FTId=VAR_053956.
FT   VARIANT      71     71       Q -> R.
FT                                /FTId=VAR_005569.
FT   VARIANT     360    360       H -> P (in dbSNP:rs4670696).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_053957.
FT   MUTAGEN     144    144       K->A: Lowers activity by approximately
FT                                40%. {ECO:0000269|PubMed:16135565}.
FT   MUTAGEN     146    146       F->A: Lowers activity by approximately
FT                                30%. {ECO:0000269|PubMed:16135565}.
FT   MUTAGEN     160    160       S->A: Reduces activity by about 50%.
FT                                {ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     160    160       S->G: Reduces activity by 96%.
FT                                {ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     201    201       E->D: Reduces activity by about 98%.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     201    201       E->L,Q: Abolishes activity.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     207    207       W->L: Greatly lowers activity.
FT                                {ECO:0000269|PubMed:16135565}.
FT   MUTAGEN     248    248       D->A: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     248    248       D->Q: Abolishes activity.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     304    304       Q->L: Lowers activity by approximately
FT                                35%. {ECO:0000269|PubMed:16135565}.
FT   MUTAGEN     305    305       D->A,E,L: Abolishes activity.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     305    305       D->N: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:16135565,
FT                                ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     319    319       H->L: Reduces activity by 87%.
FT                                {ECO:0000269|PubMed:18072935}.
FT   MUTAGEN     325    325       F->A: Greatly lowers activity.
FT                                {ECO:0000269|PubMed:16135565}.
FT   MUTAGEN     329    329       W->A: Abolishes activity.
FT                                {ECO:0000269|PubMed:16135565}.
FT   HELIX        36     38       {ECO:0000244|PDB:2AFW}.
FT   HELIX        39     42       {ECO:0000244|PDB:2AFW}.
FT   HELIX        50     59       {ECO:0000244|PDB:2AFW}.
FT   HELIX        62     68       {ECO:0000244|PDB:2AFW}.
FT   HELIX        71     73       {ECO:0000244|PDB:2AFW}.
FT   HELIX        82     96       {ECO:0000244|PDB:2AFW}.
FT   STRAND       98    100       {ECO:0000244|PDB:2AFW}.
FT   STRAND      103    111       {ECO:0000244|PDB:2AFW}.
FT   STRAND      116    128       {ECO:0000244|PDB:2AFW}.
FT   STRAND      131    140       {ECO:0000244|PDB:2AFW}.
FT   HELIX       149    151       {ECO:0000244|PDB:3PBB}.
FT   TURN        157    160       {ECO:0000244|PDB:2AFW}.
FT   HELIX       161    173       {ECO:0000244|PDB:2AFW}.
FT   HELIX       175    179       {ECO:0000244|PDB:2AFW}.
FT   HELIX       180    182       {ECO:0000244|PDB:4YWY}.
FT   STRAND      191    199       {ECO:0000244|PDB:2AFW}.
FT   STRAND      204    206       {ECO:0000244|PDB:2AFW}.
FT   STRAND      209    212       {ECO:0000244|PDB:2AFW}.
FT   HELIX       214    224       {ECO:0000244|PDB:2AFW}.
FT   STRAND      226    229       {ECO:0000244|PDB:2AFW}.
FT   TURN        237    240       {ECO:0000244|PDB:2AFW}.
FT   STRAND      241    247       {ECO:0000244|PDB:2AFW}.
FT   STRAND      252    254       {ECO:0000244|PDB:2AFW}.
FT   STRAND      257    259       {ECO:0000244|PDB:3SI0}.
FT   HELIX       262    264       {ECO:0000244|PDB:2AFW}.
FT   HELIX       265    280       {ECO:0000244|PDB:2AFW}.
FT   STRAND      284    286       {ECO:0000244|PDB:2AFW}.
FT   STRAND      293    295       {ECO:0000244|PDB:3PBB}.
FT   HELIX       308    311       {ECO:0000244|PDB:2AFW}.
FT   TURN        312    314       {ECO:0000244|PDB:2AFW}.
FT   STRAND      317    320       {ECO:0000244|PDB:2AFW}.
FT   TURN        327    330       {ECO:0000244|PDB:2AFW}.
FT   HELIX       336    338       {ECO:0000244|PDB:2AFM}.
FT   HELIX       341    359       {ECO:0000244|PDB:2AFW}.
SQ   SEQUENCE   361 AA;  40877 MW;  32C26041BCF5ED75 CRC64;
     MAGGRHRRVV GTLHLLLLVA ALPWASRGVS PSASAWPEEK NYHQPAILNS SALRQIAEGT
     SISEMWQNDL QPLLIERYPG SPGSYAARQH IMQRIQRLQA DWVLEIDTFL SQTPYGYRSF
     SNIISTLNPT AKRHLVLACH YDSKYFSHWN NRVFVGATDS AVPCAMMLEL ARALDKKLLS
     LKTVSDSKPD LSLQLIFFDG EEAFLHWSPQ DSLYGSRHLA AKMASTPHPP GARGTSQLHG
     MDLLVLLDLI GAPNPTFPNF FPNSARWFER LQAIEHELHE LGLLKDHSLE GRYFQNYSYG
     GVIQDDHIPF LRRGVPVLHL IPSPFPEVWH TMDDNEENLD ESTIDNLNKI LQVFVLEYLH
     L
//
